2ND ANNUAL
Joint Meeting (Bari/NYU)
HEREDITARY
BREAST &
OVARIAN
CANCER

September 14-17, 2011
NYU School of Medicine
Smilow Seminar Room
550 First Avenue
New York, NY 10016

Sponsored by the NYU Post-Graduate Medical School
Course Description

This program is the result of an ongoing collaboration between American and European colleagues on biomedical research and health concerns. The first congress, which took place in Bari in 2009, compiled work from both sides of the Atlantic. This year, the course will focus on ways to lessen the burden of genetic cancer risks. Genes implicated in the devastating occurrence of breast and ovarian cancer within certain high-risk families were mapped and then cloned not even two decades ago. BRCA dysfunction, risk-reducing surgeries and surveillance methods are systematically applied to high-risk populations. The results are encouraging, but such clinical interventions can lead to psychosocial ramifications requiring further study. Lines of inquiry inspired by the presence of patient advocacy will continue to remind meeting participants and interested parties of the balance between scientific pursuits and ethics.

The program will consist of 7 scientific sessions made up of oral presentations by invited speakers and additional presentations selected from registrant submitted abstracts. First sessions will focus on molecular events that have been linked with hereditary breast and ovarian cancers such as DNA repair pathways, genetic instability involving BRCA1 and PTEN, and markers of stem cell properties. Subsequent sessions will cover biological and clinical features of these two cancers, as well as therapeutic and psychosocial implications of this advancing knowledge.

Statement of Need

Oncology specialists need to continuously update their knowledge of emerging genetic components about breast and ovarian cancers and apply this knowledge to their screening and prevention strategies. Oncologists need to consider psychosocial and ethical implications when identifying high risk subjects and keep pace with scientific studies in this area. Biology of carcinogenesis and cancer stem cells needs to be integrated into the treatment plan of oncologists for patients at ‘high-risk’ of cancer. Scientists need to actively involve high-risk subjects and their families in order to conduct meaningful epidemiological studies.

Educational Objectives

• Identify studies dealing with surveillance of high-risk populations and document interventions that may reduce risks of disease
• Encourage discussions among health professionals and consider potential psychosocial and ethical implications when identifying high-risk patients
• Coordinate treatment plans for high-risk patients by incorporating the latest evidence of carcinogenesis and cancer stem cells
• Select the most appropriate high-risk subjects and their families when conducting epidemiological studies seeking to identify genetic and environmental factors contributing to breast and ovarian cancers

Target Audience

Members of the international medical community wanting to explore common and new grounds on hereditary breast and ovarian cancer, to include Clinical (Gynecologic, Surgical, and Medical) Oncology Teams and related research and health professionals.

Mission Statement

The NYU Post-Graduate Medical School is committed to training physicians to provide excellent care of patients through life-long continuing medical education of the highest quality. Our overall goal is to enhance clinical competence and performance and, where possible, improve patient outcomes.

Accreditation Statement

The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The NYU Post-Graduate Medical School designates this live activity for a maximum of 15.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
LOCATION

NYU School of Medicine
Smilow Seminar Room
550 First Avenue (31st St.)
New York, NY 10016

Please Note: Photo identification is required to enter the medical center.

HOTEL ACCOMMODATION

Rooms are in very heavy demand in New York City; we urge you to make your reservations early. You may obtain a list of hotels located near NYU School of Medicine by visiting our website http://cme.med.nyu.edu/travel

PARKING

Parking is available on 29th and 30th Streets between First and Second Avenues, as well as at the Schwartz Health Care Center garage on First Avenue and 30th Street, or visit our website http://med.nyu.edu/directions-parking.

Please Note: We cannot validate parking for registrants.

ONLINE REGISTRATION PREFERRED

Applications will be accepted in order of their receipt. Visit our secure website http://cme.med.nyu.edu/hboc to submit online registration.

MAILING ADDRESS AND CONTACT INFORMATION:

Registration Office
NYU Post-Graduate Medical School
P.O. Box 1855
Murray Hill Station, New York, NY 10016
Phone: (212)263-5295
Fax: (212)263-5293

Please Note: We cannot accept telephone registration.

COURSE CONFIRMATION

Please supply your e-mail address to receive a confirmation letter. Written confirmation will not be mailed.
**Wednesday, Sept 14**

5:00 pm  Registration & Opening Reception

**Thursday, Sept 15**

7:30 am  Registration & Continental Breakfast
8:15  Welcome and Opening Remarks  
*Franco Muggia & Angelo Paradiso*

**Session I: Molecular Events**  
*Moderators: Stefania Tommasi & Robert Schneider*

8:30  DNA Repair Pathways  
*Jeff Boyd*

9:00  Genetic Instability: BRCA1 and PTEN  
*Ramon Parsons*

9:30  Plasticity in Cancer: Non-Stem Cell De-differentiate to Cancer Stem Cells  
*Christine Chaffer*

10:00  Discussion
10:30  Coffee Break & Poster Viewing

**Session II: Breast Cancer Biology: Implications for Interventions**  
*Moderators: Helen Barcellos-Hoff & Gordon McVie*

11:00  General Challenges to Surveillance  
*Mary Ellen Warner*

11:30  Outcomes from MRI Surveillance  
*Francesco Sardanelli*

12:00 pm  Mammographic Density  
*Malcolm Pike*

12:30  Lunch & Poster Viewing
2:00  Learning from Hereditary Cancers  
*Henry Lynch*

2:45  Coffee Break & Poster Viewing

**Session III: Breast Cancer Biology: Implications for Chemoprevention & Treatment**  
*Moderators: Banu Arun & Victor Grann*

3:30  Surgical Interventions for Hereditary Breast Cancer  
*Virgilio Sacchini*

4:00  Breast Conservation: Any Consequences?  
*Silvia Formenti*

4:30  BRCA Function and Guidance for Treatment Selection (selected from submitted abstracts)
4:45  Other Selected Posters & Discussion
5:45 pm  Adjourn

**Friday, Sept 16:**

**Section IV: Ovarian Cancer Biology: Implications for Early Interventions**  
*Moderators: Lynda Roman & Andres Poveda*

8:30 am  Cell of Origin of Ovarian Cancer  
*Louis Dubeau*

**Section V: Ovarian Cancer Biology: Implications for Chemoprevention & Treatment**  
*Moderators: Tamar Safra & Mack Barnes*

11:00  Molecular Targets from Animal Models  
*Daniela Dinulescu*

11:30  Outcome of Ovarian Cancer in BRCA Mutation Carriers  
*Tamar Safra*

12:00 pm  Update on PARP Inhibitors  
*A. Hilary Calvert*

12:30  Lunch & Poster Viewing
2:00  SPECIAL PRESENTATION: Partnership in Women’s Cancer Research  
*Valerie Smaldone, introduced by John Curtin*

2:45  Coffee Break & Poster Viewing

**Session VI: Molecular Epidemiology**  
*Moderators: Paolo Radice & Richard Hayes*

3:30  Ovarian Cancer Consortium Data  
*C. Leigh Pearce*

4:00  Genetic Modifiers of Cancer Risk  
*Antonis Antoniou*

4:30  Selected Posters & Discussion
5:15 pm  Adjourn

**Saturday, Sept 17**

**Session VII: Ethical and Psychosocial Aspects of Interventions According to Genetic Risks**  
*Moderators: Sudhir Srivastava & Jeffrey Weitzel*

9:00 am  Ethical and Psychosocial Issues of BRCA Mutation Carriers  
*Antonella Surbone*

9:20  Familial Cancer Database On-line  
*Rolf Sijmons*

9:40  Ethnic Attitudes Towards Genetically-Based Biomedical Research  
*Julia Smith*

10:00  Selected Posters & Discussion
10:45  Coffee Break
11:15  Panel on Research Agenda for the Next Two Years  
*Moderator: Gordon McVie*
*Participants: Angelo Paradiso, Silvia Formenti, Antonella Surbone, Stephanie Blank, Deborah Axelrod, Darcy Spicer, Franco Muggia.*

12:30 pm  Awards and Conclusion  
Franco Muggia & Angelo Paradiso
## Course Directors

**Franco Muggia, MD**  
NYU School of Medicine  
New York, NY

**Angelo Paradiso, MD**  
Scientific Director  
National Cancer Centre “Giovanni Paolo II”  
Bari, Italy

## NYU Faculty

**Deborah M. Axelrod, MD**  
Associate Professor  
Director Clinical Breast Surgery and Community Outreach  
Department of Surgery  
NYU Breast Surgery Associates  
New York, NY

**Mary Helen Barcellos-Hoff, PhD**  
Professor, Department of Radiation Oncology  
New York, NY

**Stephanie V. Blank, MD**  
Assistant Professor  
Gynecologic Oncology Fellowship Director  
New York, NY

**Silvia C. Formenti, MD**  
The Sandra and Edward H. Meyer Professor of Radiation Oncology  
Chairman of the Department of Radiation Oncology  
New York, NY

**Richard B. Hayes, DDS, PhD, MPH**  
Professor, Department of Environmental Medicine  
(Epidemiology)  
New York, NY

**Julia A. Smith, MD, PhD**  
Clinical Assistant Professor; Department of Medicine  
NYU Medical Oncology Associates  
New York, NY

**Antonella Surbone MD, PhD, FACP**  
Adjunct Professor of Medicine  
New York, NY

## Guest Faculty

**Antonis C. Antoniou, PhD**  
Cancer Research - UK Senior Cancer Research Fellow  
University of Cambridge  
Cambridge, UK

**Bagu Arun, MD**  
Professor  
The University of Texas MD Anderson Cancer Center  
Houston, TX

**Jeff Boyd, PhD**  
Vice President, Molecular Medicine  
Fox Chase Cancer Center  
Philadelphia, PA

**A. Hilary Calvert**  
Professor  
University College London  
London, United Kingdom

**Christine L. Chaffer, PhD**  
Post-doctoral Fellow  
Whitehead Institute for Biomedical Research  
Cambridge, MA

**Daniela Dinulescu, PhD**  
Assistant Professor  
Harvard Medical School  
Brigham and Women’s Hospital  
Boston, MA

**Louis Dubéau, MD, PhD**  
Professor of Pathology  
Director of Molecular Pathology  
University of Southern California  
Los Angeles, CA

**Victor R. Grann MD, MPH**  
Clinical Professor Medicine, Epidemiology, and Health Policy  
Columbia University  
New York, NY

**Mark H. Greene, MD**  
Branch Chief  
Clinical Genetics Branch  
National Cancer Institute  
Rockville, MD

**Douglas A. Levine, MD**  
Associate Attending Surgeon  
Memorial Sloan-Kettering Cancer Center  
New York, NY

**Henry Lynch, MD**  
Chairman, Preventive Medicine & Public Health  
Professor of Medicine  
Creighton University  
Omaha, NE

**Gordon McVie, MD**  
Professor  
European Institute of Oncology  
Managing Editor  
cancer  
Milan, Italy

**Ramon Parsons, PhD**  
Professor  
Institute for Cancer Genetics  
Columbia University  
New York, NY

**Celeste Leigh Pearce, PhD, MPH**  
Assistant Professor  
University of Southern California  
Los Angeles, CA

**Malcolm C. Pike, PhD**  
Member  
Memorial Sloan-Kettering Cancer Center  
New York, NY

**Andres Poveda, MD**  
Medical Oncologist  
Fundacion IVO  
Valencia, Spain

**Paolo Radice, PhD**  
Fondazione IRCCS Istituto Nazionale dei Tumori  
Milan, Italy

**Lynda D. Roman, MD**  
Director, Division of Gynecologic Oncology  
University of Southern California  
Los Angeles, CA

**Virgilio Sacchini, MD**  
Professor of Surgery  
Weill Cornell Medical College  
Attending Surgeon  
Memorial Sloan-Kettering Cancer Center  
New York, NY

**Tamar Safra, MD**  
Tel Aviv University  
Tel Aviv Sourasky Medical Center  
Tel Aviv, Israel

**Francesco Sardanelli, MD**  
Associate Professor  
University of Milan  
Department of Radiology Department  
IRCCS Policlinico San Donato  
Milan, Italy

**Robert Schneider, PhD**  
Albert B. Sabin Professor of Microbiology and Molecular Pathogenesis; Professor of Radiation Oncology

**Rolf H. Sijmons, MD, PhD**  
Associate Professor  
Department of Genetics Medical Faculty  
University of Groningen  
Consultant Clinical Oncogenetics  
Department of Genetics  
University Medical Center Groningen  
Groningen, the Netherlands

**Valerie Smaldone**  
Patient Advocate  
Media Personality  
New York, NY

**Darcy V. Spicer, MD**  
Chief Medical Oncology  
USC/Norris Cancer Center  
Los Angeles, CA

**Sudhir Srivastava, PhD**  
National Cancer Institute  
Bethesda, MD

**Stefania Tommasi, PhD**  
Researcher  
National Cancer Centre “Giovanni Paolo II”  
Bari, Italy

**Ellen Warner, MD**  
Professor of Medicine  
University of Toronto  
Toronto, Ontario

**Jeffrey Wietzel, MD**  
Director of Clinical Cancer Genetics  
City of Hope  
Duarte, CA
CALL FOR ABSTRACTS: Research on four aspects covered in this symposium will be featured in the program, to include: 1) basic science, 2) epidemiology, 3) screening and prevention of breast and ovarian cancers, and 4) psychosocial issues.

Abstracts should follow these directions: Describe the objectives and results of the research in the abstract so that the Scientific Program Committee can evaluate the quality, originality, and completeness of the abstract. Abstracts will be judged solely on the basis of the data in the submitted abstract. Statements such as “further data will be available” are discouraged. Additional appendices, tables, or other supplementary materials will not be accepted. Organize the abstract according to four sections, identified by the following headers (in bold): Background, Methods, Results, and Conclusions. Do not exceed 2,000 characters (approximately 300-350 words) for the total of your abstract title, body, and table. List no more than 10 individual authors for each abstract. In addition to the 10 authors, an authoring group may also be listed to indicate the remaining authors. Make sure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors in the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals”. Do not refer to study results or conclusions in the title of the abstract. The title should objectively describe the study. Do not include illustrations with the abstract. You may include a data table. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract. Take particular care to identify complex chemotherapy regimens accurately.

Abstracts should be submitted online at http://nyuci.org/hboc2011. Authors wishing to be considered for $1,000 Travel Awards must have the appropriate academic official submit this request. Meritorious abstracts will be featured in presentations within the appropriate session or invited to be displayed as posters. The Program Steering Committee will also assign travel awards to selected authors by July 22nd.

Refund Policy: An administrative charge of 30% of your tuition payment will be assessed for cancellations prior to August 31, 2011. Cancellations must be in writing and postmarked no later than the above date. (Faxes and e-mails are not accepted.) Cancellations will not be accepted after the above date.

Course Cancellation Policy: In the unusual circumstance that this course is cancelled, two weeks notice will be given and tuition will be refunded in full. The NYU Post-Graduate Medical School is not responsible for any airfare, hotel or other costs incurred.
2ND ANNUAL
Joint Meeting (Bari/NYU)
HEREDITARY
BREAST &
OVARIAN
CANCER

September 14-17, 2011

Register online:
http://cme.med.nyu.edu/hboc